Paclitaxel-liposome–microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers

Yan, Fei; Lü, Li; Deng, Zhiting; Jin, Qiaofeng; Chen, Juanjuan; Yang, Wei; Yeh, Chih‐Kuang; Wu, Junru; Shandas, Robin; Liu, Xin; Zheng, Hairong

doi:10.1016/j.jconrel.2012.12.025

Cited by 217 publications

(157 citation statements)

References 33 publications

Supporting

Mentioning

150

Contrasting

Order By: Relevance

“…29 The performance and safety of current antineoplastic agents for breast carcinoma such as PTX are still far from satisfactory. 30 However, the use of PTX has been limited due to poor selectivity and low uptake efficiency in breast carcinoma tissue.…”

Section: Discussionmentioning

confidence: 99%

“…33 The result is delivery of greater amounts of drug with more efficient and immediate access to intracellular targets. For free drug, the cell uptake mechanism is a passive diffusion process, 29 while for conventional NPs, as a nontargeted delivery system, a possible endocytosis mechanism could be involved. 34 At the initial time, these three different mechanisms may show similar comprehensive effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Xiao¹,

Qin²,

Yang³

et al. 2014

IJN

View full text Add to dashboard Cite

Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet to be realized. Sulfatide is known to bind to extracellular matrix glycoproteins that are highly expressed in breast tumors. In this study, we report for the first time the combination of sulfatide and lipid perfluorooctylbromide NPs as a targeted breast cancer delivery vehicle for paclitaxel (PTX). PTX-sulfatide-containing lipid perfluorooctylbromide NPs (PTX-SNPs) were prepared using the emulsion/solvent evaporation method. PTX-SNPs exhibited a spherical shape, small particle size, high encapsulation efficiency, and a biphasic release in phosphate-buffered solution. The cytotoxicity study and cell apoptosis assay revealed that blank sulfatide-containing lipid perfluorooctylbromide NPs (SNPs) had no cytotoxicity, whereas PTX-SNPs had greater EMT6 cytotoxicity levels than PTX-lipid perfluorooctylbromide NPs (PTX-NPs) and free PTX. An in vitro cellular uptake study revealed that SNPs can deliver greater amounts of drug with more efficient and immediate access to intracellular targets. In vivo biodistribution measured using high-performance liquid chromatography confirmed that the PTX-SNPs can target breast tumor tissues to increase the accumulation of PTX in these tissues. The in vivo tumor inhibition ability of PTX-SNPs was remarkably higher than PTX-NPs and free PTX. Furthermore, toxicity studies suggested that the blank SNPs had no systemic toxicity. All results suggested that SNPs may serve as efficient PTX delivery vehicles targeting breast carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Xiao¹,

Qin²,

Yang³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…17 Briefly, a lipid solution consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (Lipoid, Ludwigshafen, Germany):PTX (Chengdu Yuancheng Biotechnology Ltd. Co., Chengdu, China): N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000) (Lipoid):cholesterol (Lipoid) at a molar ratio of 80:10:10:5 was prepared such that the final PTX concentration was 1 mg/mL. The solution was then extruded through a polycarbonate membrane with 200 nm pores.…”

Section: Preparation Of Drug-loaded Liposomes and Mbsmentioning

confidence: 99%

Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts

Shen¹,

Pi²,

Yan³

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Paclitaxel liposomes (PTX-LIPO) are a clinically promising antineoplastic drug formulation for the treatment of various extracranial cancers, excluding glioblastoma. A main reason for this is the presence of the blood–brain barrier (BBB) or blood–tumor barrier (BTB), preventing liposomal drugs from crossing at a therapeutically meaningful level. Focused ultrasound (FUS) in conjunction with microbubbles (MBs) has been suggested in many studies to be an effective approach to increase the BBB or BTB permeability. In this study, we investigated the feasibility of enhancing the delivery of PTX-LIPO in intracranial glioblastoma-bearing nude mice using pulsed low-intensity FUS exposure in the presence of MBs. Our results showed that the delivery efficiency of PTX-LIPO could be effectively improved in terms of the penetration of both the BBB in vitro and BTB in vivo by pulsed FUS sonication with a 10 ms pulse length and 1 Hz pulse repetition frequency at 0.64 MPa peak-rarefactional pressure in the presence of MBs. Quantitative analysis showed that a 2-fold higher drug concentration had accumulated in the glioblastoma 3 h after FUS treatment, with 7.20±1.18 µg PTX per g glioma tissue. Longitudinal magnetic resonance imaging analysis illustrated that the intracranial glioblastoma progression in nude mice treated with PTX-LIPO delivered via FUS with MBs was suppressed consistently for 4 weeks compared to the untreated group. The medium survival time of these tumor-bearing nude mice was significantly prolonged by 20.8%, compared to the untreated nude mice. Immunohistochemical analysis further confirmed the antiproliferation effect and cell apoptosis induction. Our study demonstrated that noninvasive low-intensity FUS with MBs can be used as an effective approach to deliver PTX-LIPO in order to improve their chemotherapy efficacy toward glioblastoma.

show abstract

“…Effective delivery systems have been synthesized and developed using physical stimuli over the years. Berndt et al [5] used a trigger temperature; Ercole et al [6] light; Yan et al [7] ultrasonic; Felber et al [8] pH and Kang and Bae [9] used enzyme. Nanomaterials with responsiveness triggers have a greater potential than traditional delivery systems [10].…”

Section: Editorialmentioning

confidence: 99%

pH-Sensitive Nanoparticles for Cancer Therapy: Is this a Real Innovation in Nanomedicine?

Camara¹,

Longo²

2017

Nano Res Appl

View full text Add to dashboard Cite

Paclitaxel-liposome–microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers

Cited by 217 publications

References 33 publications

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts

pH-Sensitive Nanoparticles for Cancer Therapy: Is this a Real Innovation in Nanomedicine?

Contact Info

Product

Resources

About